Payers, Providers

Who Should Make Medical-Necessity Decisions: AI, Insurers or Treating Physicians?

On a panel at HLTH, experts discussed prior authorization denials and who should make the final call.

Multi Layered Paper Craft Check Mark and Cross Mark in Concentric Circles on Green and Red Background Front View, Right or Wrong Choosing Concept.

Prior authorization is often a sticking point between payers and providers. But panelists at a recent HLTH discussion agreed that AI shouldn’t make final medical-necessity decisions in prior authorization; a licensed human should make the call.

“Artificial intelligence should not deny an authorization for medical necessity,” said Sean Robbins, EVP and COO of Blue Cross Blue Shield Association, on the panel. “A licensed clinician should make the call. Not review the call, they should make the call. Can you use artificial intelligence as a licensed clinician to help you in that? Absolutely, but the person, the human, the licensed clinician, should be the one making the call, not the artificial intelligence in that situation.”

Another panelist — Dr. Warris Bokhari, CEO of Claimable — agreed that it should be a qualified human making the decision on denials. However, when it comes to oncology, that qualified human should be the treating physician, not the insurance company, he argued. Claimable is a company that helps patients appeal denied health insurance claims.

presented by

“I don’t think it’s an unnamed person at an insurance company who is effectively practicing medicine [who should be making the decision],” he said. “And I know that we’re going to say that it’s a coverage decision. But to the end user, the patient, that human, it is absolutely a necessity decision. It’s a clinical decision that’s being rendered by a human who has never met the patient, never looked at their tests, never met their family, never held their hand, has no context.”

Bokhari added that he believes there should be a way to hold health plans accountable for making the wrong call. 

He cited Blue Cross and Blue Shield of Illinois, alleging that it had denied liver transplants for cancer patients using evidence that included case data from 1994. 

“For anyone who might remember 1994, ER was coming onto television. We’ve now iterated to The Pitt, so medicine has moved on. A lot of things have changed, but they’re still using the same evidence to deny,” Bokhari said.

presented by

He urged Blues plans and other insurers not to “stand in the way” of treating physicians and patients when a patient’s life may be at risk within a certain period of time.

Robbins responded that he doesn’t want there to be an inappropriate denial “in any situation ever.” He added that he thinks accountability and transparency are important, and said that the industry needs to be getting the right answers to the right people quickly.

Dr. Mandy Cohen, another panelist and national advisor of Manatt Health, stressed that the whole model needs a revamp.

“As opposed to saying, ‘How do we speed up the process?’ it’s more, ‘How do we rethink this whole process?’ … The rethink is so important here, and it’s linked to underlying payment incentives. The reason insurance companies exist and have these guardrails is because providers do ask for low-value care. Let’s be honest. That is happening,” she said.

Photo: MirageC, Getty Images